MusthInsider

Latest On Rubius Therapeutics, Inc (RUBY):

Updated on: March 18, 2021

Date/Time	Type	Description	Signal
2023-02-22 17:10 EST	News	Rubius Therapeutics adds 10% on plan for liquidation	N/A
2022-11-02 22:34 EST	News	Rubius stock falls over 5% after hours on strategic review, more job cuts	N/A
2022-09-13 17:01 EST	News	Rubius stock slumps 26% as tumor trials of RTX-240, RTX-224 axed, cuts 75% workforce	N/A
2022-08-10 05:06 EST	News	Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03	N/A
2022-06-20 00:49 EST	News	Rubius: Poor Data, Punishing Environment, Beaten Stock	N/A
2022-05-12 04:13 EST	News	Rubius price target lowered at H.C. Wainwright on trial update for cellular therapy	N/A
2022-05-10 12:59 EST	News	Rubius Therapeutics GAAP EPS of -$0.58 beats by $0.01	N/A
2022-04-26 02:06 EST	News	Rubius Therapeutics up 34% after insider buy	N/A
2022-04-12 01:29 EST	News	Rubius price targets slashed on underwhelming cancer data	N/A
2022-04-12 01:29 EST	News	Rubius Therapeutics tumbles 20% on lowered price target due to disappointing RTX-240 data	N/A
2022-04-08 20:19 EST	News	Rubius Therapeutics falls 45% after updated early-stage data on solid tumors candidate	N/A
2022-03-22 02:13 EST	News	Rubius Looks Attractive Before AACR Data Readout	N/A
2022-02-25 13:42 EST	News	Rubius Therapeutics GAAP EPS of -$0.61 misses by $0.02	N/A
2022-02-11 08:33 EST	News	Rubius Therapeutics (RUBY) Investor Presentation IP - Slideshow	N/A
2022-01-13 20:24 EST	News	Rubius Therapeutics begins dosing in phase 1/2 trial of RTX-224 for solid tumors	N/A
2022-01-13 03:55 EST	News	Rubius Therapeutics (RUBY) presents at JP Morgan 40th Annual Virtual Healthcare Conference (Slideshow)	N/A
2021-12-16 13:02 EST	News	Rubius to report additional Phase 1 data for RTX-240 in solid tumors next quarter	N/A
2021-11-08 17:58 EST	News	Rubius Therapeutics EPS beats by $0.02	N/A
2021-10-12 12:10 EST	News	Warning: RUBY is at high risk of performing badly	N/A
2021-08-09 14:04 EST	News	Rubius Therapeutics EPS misses by $0.06	N/A
2021-07-30 00:46 EST	News	Rubius Therapeutics appoints new operations chief	N/A
2021-07-21 22:12 EST	News	Rubius Therapeutics doses first patient in RTX-240 cancer study	N/A
2021-07-21 21:59 EST	News	Our Read On Rubius Therapeutics	N/A
2021-04-09 09:51 EST	News	Rubius Therapeutics to present early-stage RTX-240 study results at AACR	N/A
2021-03-17 07:30 EST	News	Rubius Therapeutics falls on initial data for RTX-240 in solid tumors	N/A
2021-03-17 07:27 EST	News	Rubius shares soar 84% on solid tumor data, Wainwright PT increase	N/A
2021-03-17 07:27 EST	News	Rubius Therapeutics secures $150M capital raise	N/A
2021-03-17 07:24 EST	News	Rubius Therapeutics prices upsized $200M public offering	N/A
2021-03-16 21:55 EST	Analyst Rating	The Analyst Target Price has increased from $13.9 to $27.4.	Buy
2021-02-27 01:01 EST	News	Rubius Therapeutics (RUBY) Presents At SVB Leerink 10th Annual Global Healthcare Conference - Slideshow	N/A
2021-02-25 14:34 EST	Financials	Company financials have been released.	Neutral
2021-02-25 14:34 EST	Analyst Rating	The Analyst Target Price has increased from $11.33 to $13.9.	Buy
2021-02-24 12:19 EST	Financials	Company financials have been released.	Neutral
2021-02-24 12:19 EST	Earnings Estimate	An EPS average of -$1.71 is estimated for the 2022 year.	Sell
2021-02-24 12:19 EST	Earnings Estimate	An EPS average of -$0.48 is estimated for the quarter ending on June 30, 2021.	Buy
2021-02-24 12:19 EST	Analyst Rating	The Analyst Target Price has decreased from $11.5 to $11.33.	Sell
2021-02-23 20:12 EST	News	Rubius Therapeutics drops 5% despite Q4 beat	N/A
2021-01-29 08:29 EST	Analyst Rating	The Analyst Target Price has increased from $10.29 to $11.5.	Neutral
2021-01-26 12:53 EST	News	Rubius: Watson, We Have No Data	N/A
2021-01-20 08:28 EST	Analyst Rating	The Analyst Target Price has increased from $9.57 to $10.29.	Buy
2021-01-15 00:40 EST	News	Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow	N/A
2021-01-12 08:28 EST	Analyst Rating	The Analyst Target Price has decreased from $10.67 to $9.57.	Neutral
2020-11-26 21:25 EST	Financials	Company financials have been released.	Neutral
2020-11-18 13:11 EST	Analyst Rating	The Analyst Target Price has increased from $9.57 to $10.67.	Buy
2020-11-12 05:09 EST	Analyst Rating	The Analyst Target Price has increased from $9.43 to $9.57.	Buy
2020-11-11 12:53 EST	Financials	Company financials have been released.	Neutral
2020-11-10 13:05 EST	Earnings Estimate	An EPS average of -$0.53 is estimated for the quarter ending on March 31, 2021.	Sell
2020-11-09 18:23 EST	News	Rubius Therapeutics EPS misses by $0.01	N/A
2020-11-08 00:47 EST	Financials	Company financials have been released.	Neutral
2020-11-07 17:02 EST	Financials	Company financials have been released.	Neutral

About Rubius Therapeutics, Inc (RUBY):

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

See Advanced Chart

General

Name Rubius Therapeutics, Inc
Symbol RUBY
Type Common Stock
Exchange NASDAQ
Currency USD
Country USA
SectorHealthcare
IndustryBiotechnology
Full Time Employees 204
Fiscal Year EndDecember
IPO Date2018-07-18
Gic SectorHealth Care
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryBiotechnology
Gic SubIndustryBiotechnology
Web URLhttp://www.rubiustx.com

Valuation

Price/Book (Most Recent Quarter) 13.87

Financials

Most Recent Quarter 2020-12-31
Current Year EPS Estimate -$2.10
Next Year EPS Estimate -$2.11
Next Quarter EPS Estimate -$0.50
Return on Assets -31%
Return on Equity -81%
Earnings Per Share -$1.70
Revenue Per Share $0
Quarterly Earnings Growth 0%

Highlights

Market Capitalization 1.97 billion
EBITDA -130160000
Analyst Target Price $27.4
Book Value Per Share $1.75

Share Statistics

Shares Outstanding 81.18 million
Shares Float 32.06 million
% Held by Insiders 799%
% Held by Institutions 94.8%
Shares Short 7.5 million
Shares Short Prior Month 7.41 million
Short Ratio 7.92
Short % of Float 28%
Short % of Shares Outstanding 9%

Technicals

Beta 2.2
52 Week High $29.63
52 Week Low $3.83
50 Day Moving Average 13.94
200 Day Moving Average 8.21

Dividends

Dividend Date N/A
ExDividend Date N/A
Dividend Yield 0%

Rubius Therapeutics, Inc (RUBY) Dividend Calendar:

Ex-Dividend Date	Payment Date	Record Date	Declared Date	Amount

Rubius Therapeutics, Inc (RUBY) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.

Quarter Date	Report Date	Actual Revenue	Reported EPS	EPS Estimate	Deviation from Estimate
2020-12-31	2021-02-23	$N/A	-$0.50	-$0.53	4.94%
2020-09-30	2020-11-09	$N/A	-$0.51	-$0.50	-2.7%
2020-06-30	2020-08-10	$N/A	-$0.47	-$0.50	6.47%
2020-03-31	2020-05-11	$N/A	-$0.60	-$0.56	-7.89%
2019-12-31	2020-03-12	$N/A	-$0.56	-$0.64	12.57%
2019-09-30	2019-11-14	$N/A	-$0.59	-$0.56	-5.56%
2019-06-30	2019-08-13	$N/A	-$0.50	-$0.48	-3.28%
2019-03-31	2019-05-15	$N/A	-$0.42	-$0.41	-1.35%
2018-12-31	2019-03-28	$N/A	-$0.35	-$0.42	16.51%
2018-09-30	2018-11-13	$N/A	-$0.42	-$0.36	-16.54%
2018-06-30	2018-08-31	$N/A	-$0.43	-$0.30	-41.68%

Rubius Therapeutics, Inc (RUBY) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:

Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares

Cash Flow:

Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures

Balance Sheet:

Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Rubius Therapeutics, Inc (RUBY) Chart:

Rubius Therapeutics, Inc (RUBY) News:

Below you will find a list of latest news for Rubius Therapeutics, Inc (RUBY) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Rubius Therapeutics, Inc (RUBY) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date	Strike	Last Price	Type	Volume	Open Interest	Implied Volatility	In The Money	Change	Change Percent

Latest RUBY Trades:

Date	Shares	Price
Jun 13, 2022 7:59 PM EST	200	$0.8926
Jun 13, 2022 7:59 PM EST	7	$0.8926
Jun 13, 2022 7:59 PM EST	68	$0.8926
Jun 13, 2022 7:59 PM EST	21	$0.8926
Jun 13, 2022 7:59 PM EST	95	$0.8926

Rubius Therapeutics, Inc (RUBY) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date	Form Type	Form Name	Link
2020-06-30	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465920078435/0001104659-20-078435-index.htm
2019-08-08	UPLOAD	SEC-generated letter	https://www.sec.gov/Archives/edgar/data/1709401/000000000019012197/0000000000-19-012197-index.htm
2019-02-13	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1709401/000031506619001262/0000315066-19-001262-index.htm
2019-11-12	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1709401/000031506619001755/0000315066-19-001755-index.htm
2020-02-07	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1709401/000031506620001145/0000315066-20-001145-index.htm
2018-07-18	424B4	Prospectus [Rule 424(b)(4)]	https://www.sec.gov/Archives/edgar/data/1709401/000104746918005073/0001047469-18-005073-index.htm
2019-04-12	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1709401/000104746919002211/0001047469-19-002211-index.htm
2019-08-01	S-3	Registration statement under Securities Act of 1933	https://www.sec.gov/Archives/edgar/data/1709401/000104746919004493/0001047469-19-004493-index.htm
2020-04-09	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1709401/000104746920002200/0001047469-20-002200-index.htm
2019-01-15	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1709401/000108887519000014/0001088875-19-000014-index.htm
2020-01-17	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1709401/000108887520000018/0001088875-20-000018-index.htm
2018-07-17	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918045597/0001104659-18-045597-index.htm
2018-07-17	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918045598/0001104659-18-045598-index.htm
2018-07-17	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918045599/0001104659-18-045599-index.htm
2018-07-17	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918045600/0001104659-18-045600-index.htm
2018-07-17	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918045601/0001104659-18-045601-index.htm
2018-07-18	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1709401/000110465918045764/0001104659-18-045764-index.htm
2018-07-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918045771/0001104659-18-045771-index.htm
2018-07-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918045772/0001104659-18-045772-index.htm
2018-07-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918045773/0001104659-18-045773-index.htm
2018-07-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918045774/0001104659-18-045774-index.htm
2018-07-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918045775/0001104659-18-045775-index.htm
2018-07-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918045776/0001104659-18-045776-index.htm
2018-07-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918045777/0001104659-18-045777-index.htm
2018-07-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918045778/0001104659-18-045778-index.htm
2018-07-23	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465918046523/0001104659-18-046523-index.htm
2018-07-23	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918046526/0001104659-18-046526-index.htm
2018-07-23	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918046528/0001104659-18-046528-index.htm
2018-07-23	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918046530/0001104659-18-046530-index.htm
2018-07-23	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918046532/0001104659-18-046532-index.htm
2018-07-23	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918046534/0001104659-18-046534-index.htm
2018-07-25	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465918046838/0001104659-18-046838-index.htm
2018-08-01	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465918048790/0001104659-18-048790-index.htm
2018-08-31	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465918054635/0001104659-18-054635-index.htm
2018-08-31	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1709401/000110465918054637/0001104659-18-054637-index.htm
2018-11-01	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465918065519/0001104659-18-065519-index.htm
2018-11-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465918067460/0001104659-18-067460-index.htm
2018-11-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465918067738/0001104659-18-067738-index.htm
2018-11-13	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1709401/000110465918067739/0001104659-18-067739-index.htm
2018-12-21	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465918074479/0001104659-18-074479-index.htm
2019-01-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919002512/0001104659-19-002512-index.htm
2019-01-22	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465919002584/0001104659-19-002584-index.htm
2019-01-24	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919003193/0001104659-19-003193-index.htm
2019-02-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919005603/0001104659-19-005603-index.htm
2019-02-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919005604/0001104659-19-005604-index.htm
2019-02-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919005605/0001104659-19-005605-index.htm
2019-02-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919005606/0001104659-19-005606-index.htm
2019-02-14	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1709401/000110465919008821/0001104659-19-008821-index.htm
2019-02-14	5	Annual statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919008822/0001104659-19-008822-index.htm
2019-03-11	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465919013736/0001104659-19-013736-index.htm
2019-03-19	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919016067/0001104659-19-016067-index.htm
2019-03-25	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465919017131/0001104659-19-017131-index.htm
2019-03-27	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919017892/0001104659-19-017892-index.htm
2019-03-28	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465919018062/0001104659-19-018062-index.htm
2019-04-01	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919019036/0001104659-19-019036-index.htm
2019-04-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919020219/0001104659-19-020219-index.htm
2019-04-10	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919020731/0001104659-19-020731-index.htm
2019-04-12	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material	https://www.sec.gov/Archives/edgar/data/1709401/000110465919021135/0001104659-19-021135-index.htm
2019-04-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919022064/0001104659-19-022064-index.htm
2019-05-23	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465919031516/0001104659-19-031516-index.htm
2019-05-28	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919032118/0001104659-19-032118-index.htm
2019-05-28	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919032119/0001104659-19-032119-index.htm
2019-05-28	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919032120/0001104659-19-032120-index.htm
2019-05-28	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919032121/0001104659-19-032121-index.htm
2019-05-28	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919032122/0001104659-19-032122-index.htm
2019-05-28	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919032123/0001104659-19-032123-index.htm
2019-05-28	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919032124/0001104659-19-032124-index.htm
2019-06-19	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919036506/0001104659-19-036506-index.htm
2019-06-24	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919037241/0001104659-19-037241-index.htm
2019-07-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919040757/0001104659-19-040757-index.htm
2019-07-26	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919042118/0001104659-19-042118-index.htm
2019-08-09	CORRESP	Correspondence	https://www.sec.gov/Archives/edgar/data/1709401/000110465919045115/0001104659-19-045115-index.htm
2019-08-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465919045429/0001104659-19-045429-index.htm
2019-08-19	CORRESP	Correspondence	https://www.sec.gov/Archives/edgar/data/1709401/000110465919046536/0001104659-19-046536-index.htm
2019-09-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919050627/0001104659-19-050627-index.htm
2019-10-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919054477/0001104659-19-054477-index.htm
2019-11-14	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465919063717/0001104659-19-063717-index.htm
2019-11-20	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919065987/0001104659-19-065987-index.htm
2019-12-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919069692/0001104659-19-069692-index.htm
2019-12-18	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465919073590/0001104659-19-073590-index.htm
2019-12-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919073955/0001104659-19-073955-index.htm
2019-12-23	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465919075314/0001104659-19-075314-index.htm
2019-12-26	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465919076260/0001104659-19-076260-index.htm
2020-01-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465920000769/0001104659-20-000769-index.htm
2020-01-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465920003243/0001104659-20-003243-index.htm
2020-01-13	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465920003444/0001104659-20-003444-index.htm
2020-01-28	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465920007739/0001104659-20-007739-index.htm
2020-01-31	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465920009345/0001104659-20-009345-index.htm
2020-02-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465920010062/0001104659-20-010062-index.htm
2020-02-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465920010063/0001104659-20-010063-index.htm
2020-02-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465920010064/0001104659-20-010064-index.htm
2020-02-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465920010065/0001104659-20-010065-index.htm
2020-03-12	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465920032144/0001104659-20-032144-index.htm
2020-03-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465920034857/0001104659-20-034857-index.htm
2020-03-19	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465920036113/0001104659-20-036113-index.htm
2020-04-09	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material	https://www.sec.gov/Archives/edgar/data/1709401/000110465920044866/0001104659-20-044866-index.htm
2020-04-15	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000110465920047001/0001104659-20-047001-index.htm
2020-05-11	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465920059157/0001104659-20-059157-index.htm
2020-05-22	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465920065450/0001104659-20-065450-index.htm
2020-06-30	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465920078435/0001104659-20-078435-index.htm
2020-08-10	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465920092420/0001104659-20-092420-index.htm
2020-09-28	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000110465920109133/0001104659-20-109133-index.htm
2020-04-24	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000117911020005089/0001179110-20-005089-index.htm
2020-05-19	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000117911020006356/0001179110-20-006356-index.htm
2020-05-26	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000117911020006601/0001179110-20-006601-index.htm
2020-05-26	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000117911020006602/0001179110-20-006602-index.htm
2020-05-26	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000117911020006603/0001179110-20-006603-index.htm
2020-05-26	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000117911020006604/0001179110-20-006604-index.htm
2020-05-26	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000117911020006605/0001179110-20-006605-index.htm
2020-05-26	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000117911020006606/0001179110-20-006606-index.htm
2020-05-26	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000117911020006611/0001179110-20-006611-index.htm
2020-10-08	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1709401/000117911020010359/0001179110-20-010359-index.htm
2019-02-13	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1709401/000119312519036248/0001193125-19-036248-index.htm
2020-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1709401/000142284920000105/0001422849-20-000105-index.htm
2019-03-28	10-K	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1709401/000155837019002516/0001558370-19-002516-index.htm
2019-05-15	10-K/A	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1709401/000155837019005041/0001558370-19-005041-index.htm
2019-05-15	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1709401/000155837019005043/0001558370-19-005043-index.htm
2019-05-15	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1709401/000155837019005047/0001558370-19-005047-index.htm
2019-05-15	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1709401/000155837019005049/0001558370-19-005049-index.htm
2019-08-13	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1709401/000155837019008018/0001558370-19-008018-index.htm
2019-11-14	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1709401/000155837019010992/0001558370-19-010992-index.htm
2020-03-12	10-K	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1709401/000155837020002475/0001558370-20-002475-index.htm
2020-03-12	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1709401/000155837020002477/0001558370-20-002477-index.htm
2020-05-11	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1709401/000155837020006124/0001558370-20-006124-index.htm
2020-08-10	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1709401/000155837020010055/0001558370-20-010055-index.htm
2018-07-17	EFFECT	Notice of Effectiveness	https://www.sec.gov/Archives/edgar/data/1709401/999999999518001813/9999999995-18-001813-index.htm
2019-08-21	EFFECT	Notice of Effectiveness	https://www.sec.gov/Archives/edgar/data/1709401/999999999519001940/9999999995-19-001940-index.htm

Rubius Therapeutics, Inc (RUBY) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Rubius Therapeutics, Inc (RUBY). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 799%
Institutional Ownership: 9480%

Transaction Date	Insider Name	Insider Title	Type	Shares Number	Shares Price	Total Transaction	Shares Held After Transaction	Link
2019-01-14	ROBERT LANGER	Director	Sell	7,500.00	14.59	109,443.75	0.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919002512/0001104659-19-002512-index.htm
2019-04-15	ROBERT LANGER	Director	Sell	7,500.00	17.57	131,799.00	0.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919022064/0001104659-19-022064-index.htm
2019-07-15	ROBERT LANGER	Director	Sell	7,500.00	14.94	112,048.50	0.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919040757/0001104659-19-040757-index.htm
2019-10-14	ROBERT LANGER	Director	Sell	7,500.00	8.52	63,874.50	0.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919054477/0001104659-19-054477-index.htm
2018-07-20	Roger Pomerantz	Director	Buy	100.00	23.00	2,300.00	100.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465918046530/0001104659-18-046530-index.htm
2018-07-20	Francis M Cuss	Director	Buy	10,000.00	23.00	230,000.00	10,000.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465918046528/0001104659-18-046528-index.htm
2019-04-08	TORBEN STRAIGHT NISSEN	President	Sell	2,100.00	20.00	42,000.00	1,845,304.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919020731/0001104659-19-020731-index.htm
2019-04-05	TORBEN STRAIGHT NISSEN	President	Sell	12,096.00	20.00	241,920.00	1,847,404.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919020219/0001104659-19-020219-index.htm
2019-04-03	TORBEN STRAIGHT NISSEN	President	Sell	500.00	20.00	10,000.00	1,859,500.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919020219/0001104659-19-020219-index.htm
2020-04-22	Christina M. Coughlin	Chief Medical Officer	Buy	19,000.00	5.52	104,813.50	19,000.00	https://www.sec.gov/Archives/edgar/data/1709401/000117911020005089/0001179110-20-005089-index.htm
2019-07-24	TORBEN STRAIGHT NISSEN	President	Buy	175,000.00	0.18	31,500.00	2,020,304.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919042118/0001104659-19-042118-index.htm
2019-07-24	TORBEN STRAIGHT NISSEN	President	Buy	32,146.00	0.19	6,107.74	2,052,450.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919042118/0001104659-19-042118-index.htm
2020-04-14	PABLO J CAGNONI	CEO and President	Buy	21,000.00	4.70	98,693.70	21,000.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465920047001/0001104659-20-047001-index.htm
2018-07-20	Catherine A. Sohn	Director	Buy	2,500.00	23.00	57,500.00	2,500.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465918046532/0001104659-18-046532-index.htm
2018-07-20	Jonathan Symonds	Director	Buy	25,000.00	23.00	575,000.00	25,000.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465918046526/0001104659-18-046526-index.htm
2019-01-22	CHRISTOPHER L. CARPENTER	Chief Medical Officer	Buy	34,843.00	2.87	99,999.41	34,843.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919003193/0001104659-19-003193-index.htm
2019-03-15	CHRISTOPHER L. CARPENTER	Chief Medical Officer	Sell	48,000.00	15.84	760,113.60	34,843.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919016067/0001104659-19-016067-index.htm
2019-06-17	CHRISTOPHER L. CARPENTER	Chief Medical Officer	Sell	18,500.00	14.10	260,868.50	34,843.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919036506/0001104659-19-036506-index.htm
2019-06-18	CHRISTOPHER L. CARPENTER	Chief Medical Officer	Sell	10,858.00	14.27	154,957.78	34,843.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919036506/0001104659-19-036506-index.htm
2019-06-19	CHRISTOPHER L. CARPENTER	Chief Medical Officer	Sell	18,399.00	13.80	253,867.56	34,843.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919036506/0001104659-19-036506-index.htm
2019-06-20	CHRISTOPHER L. CARPENTER	Chief Medical Officer	Sell	243.00	13.93	3,385.96	34,843.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919037241/0001104659-19-037241-index.htm
2019-09-16	CHRISTOPHER L. CARPENTER	Chief Medical Officer	Sell	36,123.00	10.13	365,897.09	34,843.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919050627/0001104659-19-050627-index.htm
2019-09-17	CHRISTOPHER L. CARPENTER	Chief Medical Officer	Sell	11,877.00	10.05	119,309.22	34,843.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919050627/0001104659-19-050627-index.htm
2019-12-16	CHRISTOPHER L. CARPENTER	Chief Medical Officer	Sell	48,000.00	13.48	646,900.80	34,843.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919073955/0001104659-19-073955-index.htm
2019-06-20	CHRISTOPHER L. CARPENTER	Chief Medical Officer	Buy	243.00	2.87	697.41	35,086.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919037241/0001104659-19-037241-index.htm
2019-06-18	CHRISTOPHER L. CARPENTER	Chief Medical Officer	Buy	10,858.00	2.87	31,162.46	45,701.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919036506/0001104659-19-036506-index.htm
2019-09-17	CHRISTOPHER L. CARPENTER	Chief Medical Officer	Buy	11,877.00	2.87	34,086.99	46,720.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919050627/0001104659-19-050627-index.htm
2020-03-13	David R Epstein	Director	Buy	5,000.00	3.82	19,100.00	4,805,453.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465920034857/0001104659-20-034857-index.htm
2020-03-13	David R Epstein	Director	Buy	5,000.00	4.00	20,000.00	4,810,453.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465920034857/0001104659-20-034857-index.htm
2020-03-17	David R Epstein	Director	Buy	5,000.00	3.76	18,800.00	4,815,453.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465920036113/0001104659-20-036113-index.htm
2020-05-15	ANDREW M. OH	Chief Financial Officer	Buy	5,000.00	4.74	23,700.00	5,000.00	https://www.sec.gov/Archives/edgar/data/1709401/000117911020006356/0001179110-20-006356-index.htm
2019-06-19	CHRISTOPHER L. CARPENTER	Chief Medical Officer	Buy	18,399.00	2.87	52,805.13	53,242.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919036506/0001104659-19-036506-index.htm
2019-06-17	CHRISTOPHER L. CARPENTER	Chief Medical Officer	Buy	18,500.00	2.87	53,095.00	53,343.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919036506/0001104659-19-036506-index.htm
2019-09-16	CHRISTOPHER L. CARPENTER	Chief Medical Officer	Buy	36,123.00	2.87	103,673.01	70,966.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919050627/0001104659-19-050627-index.htm
2019-01-14	ROBERT LANGER	Director	Buy	7,500.00	0.15	1,125.00	7,500.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919002512/0001104659-19-002512-index.htm
2019-04-15	ROBERT LANGER	Director	Buy	7,500.00	0.15	1,125.00	7,500.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919022064/0001104659-19-022064-index.htm
2019-07-15	ROBERT LANGER	Director	Buy	7,500.00	0.15	1,125.00	7,500.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919040757/0001104659-19-040757-index.htm
2019-10-14	ROBERT LANGER	Director	Buy	7,500.00	0.15	1,125.00	7,500.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919054477/0001104659-19-054477-index.htm
2019-03-15	CHRISTOPHER L. CARPENTER	Chief Medical Officer	Buy	48,000.00	2.87	137,760.00	82,843.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919016067/0001104659-19-016067-index.htm
2019-12-16	CHRISTOPHER L. CARPENTER	Chief Medical Officer	Buy	48,000.00	2.87	137,760.00	82,843.00	https://www.sec.gov/Archives/edgar/data/1709401/000110465919073955/0001104659-19-073955-index.htm

Rubius Therapeutics, Inc

(NASDAQ:RUBY)